<DOC>
	<DOCNO>NCT01989780</DOCNO>
	<brief_summary>To evaluate optimal usage bevacizumab compare well , continue bevacizumab paclitaxel switch hormonal maintenance therapy follow bevacizumab+paclitaxel induction therapy bevacizumab+paclitaxel . To examine biomarkers monitor marker study treatment exploratory analysis .</brief_summary>
	<brief_title>Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy Advanced Metastatic ER-positive Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma breast 2 . Female aged 2075 year old get informed consent 3 . HER2 negative disease ( IHC 0/1+ 2+ FISH negative ) 4 . Documented estrogen receptor ( ER ) positive ( &gt; =1 % IHC ) 5 . Inoperative locally advance metastatic breast cancer enrolment 6 . Performance status ( ECOG ) : 01 enrolment 7 . Life expectancy least 3 month enrolment 8 . No prior systemic therapy recurrent breast cancer ( exclude hormone therapy ) 9 . No prior neo and/or adjuvant chemotherapy taxane adjuvant set diseasefree interval completion taxane treatment metastatic diagnosis &gt; = 12 month 10 . Patients measurable lesion regard Response Evaluation Criteria Solid Tumors ( RECIST ) criteria evaluable lesion 11 . Patients bone lesion acceptable osteolytic lesion measurable soft tissue component MRI CT 12 . No influence protocol treatment consider case prior therapy examination . 13 . Adequate follow organ function within 2 week start treatment . The late examination result adopt blood transfusion treatment hematopoietic factor drug allow 2 week examination . Absolute neutrophil count &gt; = 1500 /mm3 white blood cell ( WBC ) count &gt; = 3000 /mm3 Platelets &gt; =10 x 10000 /mm3 Hb &gt; = 9 g/dL Total bilirubin &lt; = 1.5 mg/dL aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 100 international unit ( IU ) /L Serum creatinine &lt; = 1.5 mg/dL Urine dipstick proteinuria &lt; = 1+ 14 . Written inform consent sign patient complete treatment related procedure 1 . Prior therapy bevacizumab 2 . Active infection require intrvenous antibiotic enrollment infection active HBV and/or HCV . 3 . Pregnancy , lactetion case potentialy pregnancy woman Not mind contraception trial period . 4 . Known hypersensitivity bevacizumab paclitaxel 5 . History hemoptysis ( &gt; = 2.5mL bright red blood per episord ) . 6 . Use disulfiram , cyanamide , carmofur procarbazine Hydrochloride 7 . Patients CNS metastasis ( except symptomatic ) 8 . Persistent Grade &gt; = 2 sensory neuropathy enrollment 9 . Grade 3 &gt; = hypertension ( &gt; = 2 use antihypertensive drug ) 10 . Evidence arterial thromboembolism ( Cerebral infarction , Myocardial infarction ) history within 1 year prior enrollment . 11 . Evidence withvenous thromboembolism ( deep vein thrombosis , pulmonary embolism ) history within 1 year prior enrollment . 12 . History GI perforation and/or serious abdominal fistula within 1 year prior enrollment 13 . Cases investigator judged inappropriate subject clinical study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>